WAVE Life Sciences Ltd. (NASDAQ:WVE) is set to announce its earnings results on Monday, August 14th. Analysts expect the company to announce earnings of ($0.78) per share for the quarter.

WAVE Life Sciences (NASDAQ:WVE) last released its quarterly earnings data on Wednesday, May 10th. The company reported ($0.89) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.77) by $0.12. The firm had revenue of $0.68 million for the quarter, compared to analysts’ expectations of $0.80 million. WAVE Life Sciences had a negative return on equity of 48.16% and a negative net margin of 3,172.14%. On average, analysts expect WAVE Life Sciences to post $-3.31 EPS for the current fiscal year and $-3.27 EPS for the next fiscal year.

Shares of WAVE Life Sciences Ltd. (WVE) opened at 20.10 on Monday. The stock’s 50 day moving average is $19.11 and its 200 day moving average is $23.57. WAVE Life Sciences Ltd. has a 52-week low of $15.15 and a 52-week high of $40.15. The stock’s market capitalization is $557.11 million.

In other WAVE Life Sciences news, insider Michael A. Panzara sold 7,414 shares of the firm’s stock in a transaction on Wednesday, July 12th. The shares were sold at an average price of $16.67, for a total transaction of $123,591.38. Following the completion of the transaction, the insider now directly owns 15,336 shares of the company’s stock, valued at approximately $255,651.12. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 53.00% of the stock is owned by company insiders.

A number of equities research analysts recently weighed in on WVE shares. Jefferies Group LLC set a $42.00 price target on shares of WAVE Life Sciences and gave the company a “buy” rating in a report on Thursday, June 8th. JMP Securities reissued an “outperform” rating and set a $40.00 price objective on shares of WAVE Life Sciences in a report on Friday, June 9th. Zacks Investment Research lowered shares of WAVE Life Sciences from a “hold” rating to a “sell” rating in a report on Thursday, July 27th. Finally, ValuEngine lowered shares of WAVE Life Sciences from a “hold” rating to a “sell” rating in a report on Friday, June 16th. Two equities research analysts have rated the stock with a sell rating and four have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $42.00.

ILLEGAL ACTIVITY WARNING: This news story was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another domain, it was stolen and republished in violation of United States and international copyright & trademark laws. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/08/07/wave-life-sciences-ltd-wve-to-release-quarterly-earnings-on-monday.html.

About WAVE Life Sciences

WAVE Life Sciences Ltd. is a genetic medicines company. The Company, through its synthetic chemistry drug development platform, designs, develops and commercializes a pipeline of nucleic acid therapeutic candidates for genetically defined diseases. The Company is engaged in developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.

Receive News & Ratings for WAVE Life Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for WAVE Life Sciences Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.